April 9, 2021April 9, 2021
$5M Donation From Grateful Patient Helps VCU Health Expand PF Care

Thanks to a $5 million donation from a grateful patient, Virginia Commonwealth University (VCU) Health is expanding its programs to treat those with lung diseases ... Read more
April 8, 2021April 6, 2021
What It Means When I Say I Had a ‘Bad Clinic Day’

Outpatient pulmonology appointments are common for people with idiopathic pulmonary fibrosis (IPF). The frequency of these appointments varies, depending on how the disease progresses, ... Read more
April 7, 2021April 7, 2021
Amgen to Acquire Rodeo Therapeutics, Preclinical Program for PF

Amgen will acquire Rodeo Therapeutics, along with its preclinical program focused on the development of potential therapies for inflammatory and fibrotic diseases like pulmonary fibrosis ... Read more
April 6, 2021April 6, 2021
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice

Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data ... Read more
April 5, 2021April 5, 2021
FDA Approves Tyvaso, 1st Treatment Aiding Exercise With PH-ILD

Tyvaso (inhaled treprostinil) has been approved as the first treatment to improve exercise ability in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

April 27, 2018April 27, 2018

Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests

News

Treatment with plant-derived aloperine reduces the severity of lung injury in a mouse model of pulmonary fibrosis, a new Chinese study reports. The research, “Aloperine Protects Mice against Bleomycin-induced Pulmonary Fibrosis by Attenuating Fibroblast Proliferation and Differentiation,” was published in ... Read more

$5M Donation From Grateful Patient Helps VCU Health Expand PF Care

What It Means When I Say I Had a ‘Bad Clinic Day’

Amgen to Acquire Rodeo Therapeutics, Preclinical Program for PF

Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice

FDA Approves Tyvaso, 1st Treatment Aiding Exercise With PH-ILD

FDA Approves Tyvaso, 1st Treatment Aiding Exercise With PH-ILD

KL-6 Protein Found to Be a Promising Biomarker for IPF Prognosis

How COVID-19 Has Shifted People’s Lives and Habits

Cost of Rare Diseases in US? Nearly $1 Trillion in 2019, EveryLife Foundation Finds

Ofev’s Ability to Slow Decline in Progressing ILDs Not Dependent on Prior Therapy

IPF Diagnosis and Treatment Changing for Better in UK, Registry Study Finds

Subscribe to our mailing list

Finding Peace and Power With Breathing Exercises

Fine Particulate Air Pollutants Raise Risk of Acute IPF Flare-ups

The Pandemic Is Stealing My Already Limited Time

Weighing Risks and Rewards as a Lung Transplant Patient

PulmoSIM Launched to Repurpose Medications for Rare Lung Conditions

Pollutants and Cigarette Smoke Trigger Protein to Possibly Cause IPF

Pitt, Yale Universities Join Consortium to Advance Therapy Development

In Webinar, Expert Discusses Strategies to Improve Quality of Life

My Age Prevents Me From Participating in Clinical Trials

CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

GALACTIC-1 Trial of Inhaled IPF Therapy to Stop High Dose, Restrict Low Dose

MDM4 Protein May Help to Treat PF by Clearing Cells That Drive Fibrosis

As a Carer, I’m Conflicted About Getting the COVID-19 Vaccine So Early

Peptide-coated Nanoparticles Limit Damage of IPF, Early Study Finds

Caring for My Mom When Her Lifesaving Organ Brought Hereditary Risk

Pesticide Exposure, Agricultural Work Linked to Increased Risk of IPF

Pink, Green, Blue and Purple Lights Illuminated World for Rare Disease Day

Viral and Bacterial Infections in Lungs May Promote IPF

Ofev Costs to Treat PF-ILD Should Be Reimbursed in Canada, Groups Say

LUNGguard System Used for 1st Time With IPF Patient’s Transplant

Reflecting on the Commonalities That Exist Among Rare Disease Patients

Preclinical Study Will Probe Potency of Cymerus MSCs

Potential IPF Treatment, Found Using AI, May Move Into Trial, Insilico Says

MYMD-1 Shows Promise in Reducing Drivers of IPF Inflammation, Fibrosis

The Courage Crew Is Running for Rare Disease Day

Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests